Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to (1) to determine the rate of PSA decline (the number
declining). Tissue will be obtained for ancillary studies and (2) to determine the number of
patients with a PSA decline to <1.0 ng/ml at 3 months in patients receiving Nexrutine® with
standard radiation therapy. The Secondary Objective is to confirm the tolerability of this
regimen. The Third Objective (Ancillary studies) is To evaluate the molecular response of
Nexrutine®. Molecular response is defined as changes in the molecular pathways.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio